High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studie...

por Ständer, S., Bhatia, N., Gooderham, M. J., Silverberg, J. I., Thyssen, J. P., Biswas, P., DiBonaventura, M., Romero, W., Farooqui, S. A.
Publicado 2022

Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis

por Silverberg, J.I., Thyssen, J.P., Fahrbach, K., Mickle, K., Cappelleri, J.C., Romero, W., Cameron, M.C., Myers, D.E., Clibborn, C., DiBonaventura, M.
Publicado 2021

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

por Thyssen, J.P., Yosipovitch, G., Paul, C., Kwatra, S.G., Chu, C.‐Y., DiBonaventura, M., Feeney, C., Zhang, F., Myers, D., Rojo, R., Valdez, H.
Publicado 2021

Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review

por Silverberg, J.I., Feldman, S.R., Smith Begolka, W., Johnson, M.B., Stanojev, C., DiBonaventura, M., Rojo Cella, R., Valdez, H., Feeney, C., Thyssen, J.P.
Publicado 2022

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement

por Drucker, A.M., Eyerich, K., de Bruin‐Weller, M.S., Thyssen, J.P., Spuls, P.I., Irvine, A.D., Girolomoni, G., Dhar, S., Flohr, C., Murrell, D.F., Paller, A.S., Guttman‐Yassky, E.
Publicado 2018

Care pathways in atopic dermatitis: a retrospective population‐based cohort study

por von Kobyletzki, L., Ballardini, N., Henrohn, D., Neary, M.P., Ortsäter, G., Geale, K., Rieem Dun, A., Lindberg, I., De Geer, A., Neregård, P., Cha, A., Cappelleri, J.C., Romero, W., Thyssen, J.P.
Publicado 2022

The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group

por Alexander, H., Paller, A.S., Traidl‐Hoffmann, C., Beck, L.A., De Benedetto, A., Dhar, S., Girolomoni, G., Irvine, A.D., Spuls, P., Su, J., Thyssen, J.P., Vestergaard, C., Werfel, T., Wollenberg, A., Deleuran, M., Flohr, C.
Publicado 2019

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion

por Thyssen, J.P., de Bruin‐Weller, M.S., Paller, A.S., Leshem, Y.A., Vestergaard, C., Deleuran, M., Drucker, A.M., Foelster‐Holst, R., Traidl‐Hoffmann, C., Eyerich, K., Taieb, A., Su, J.C., Bieber, T., Cork, M.J., Eichenfield, L.F., Guttman‐Yassky, E., Wollenberg, A.
Publicado 2019

Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe

por de Graaf, M., Janmohamed, S.R., Schuttelaar, M.L.A., Agner, T., Alfonso, J.H., De Schepper, S., Deleuran, M., Despontin, K., Elenius, V., Ghislain, P.‐D., Huilaja, L., Johansson, E.K., Kvenshagen, B.K., Mandelin, J.M., Olset, H., Svensson, A., van Tuyll van Serooskerken, A.M., Thyssen, J.P., Vestergaard, C.
Publicado 2022